ijms-logo

Journal Browser

Journal Browser

Special Issue "Gender Medicine: Pharmacogenetics and Personalised Medicine 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editors

Prof. Dr. Donato Gemmati
E-Mail Website
Guest Editor
Associate Professor in Medical Genetics, Section of Medical Biochemistry, Molecular Biology & Genetics, Dpt. of Biomedical and Specialty Surgical Sciences, University of Ferrara, I-44100 Ferrara, Italy
Interests: pharmacogenetics/genomics, precision medicine and gender medicine in inherited thrombophilia and cardiovascular disease; coagulation and inherited bleeding disorders; SNPs in iron homeostasis and folate pathways; genetics of wound healing; childhood haematological malignancies
Special Issues and Collections in MDPI journals
Prof. Dr. Veronica Tisato
E-Mail Website
Guest Editor
Department of Morphology, Surgery & Experimental Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy
Interests: translational research; gender medicine; regenerative medicine; personalized and precision medicine; focus on inflammation and biomarkers in cardiovascular and complex diseases; aging; neurodegenerative/cognitive impairment diseases
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

In the era of individualized and precision medicine, where pharmacogenetics and genomics have key roles, Gender Medicine should be considered an essential step for Personalised Medicine. Patient-centered care defines the third millennium health-care goal. The role of both sex and gender in physiological and pathophysiological processes of diseases is becoming crucial in terms of efficient prevention, clinical signs identification, prognosis, therapies optimisation, as well as in terms of social-psychological and cost-effective impact. Accordingly, viewing patients through a sex and gender lens is a novel and promising approach. Personalized healthcare must be based on evidence derived from targeted research studies aimed at understanding how different sex and hormonal status influence health across the life-span. To understand the genetic, molecular and biochemical bases of the existing “gap” among patients will pave the way to discovering and identifying novel drug-targets and designing new therapeutic protocols together with personalized laboratory tests. A modern project to successfully integrate gender and sex differences and precision medicine should include gender and sex specific oriented researches.

In this Special Issue, we focus on how gender-oriented precision medicine can be translated from bench to bedside. We welcome original papers and review articles that focus on the latest advances on the molecular research of gender medicine. Gender medicine in different disciplines including cardiology, endocrinology, pharmacology, oncology, dermatology, infection disease, geriatrics and aging, gastroenterology, and neurology are welcome.

Prof. Dr. Donato Gemmati
Prof. Dr. Veronica Tisato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
Int. J. Mol. Sci. 2021, 22(3), 1381; https://doi.org/10.3390/ijms22031381 - 30 Jan 2021
Cited by 1 | Viewed by 600
Abstract
Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) in 13 of these genes to predict tumour response and clinical outcome measured as progression free survival (PFS) and overall survival [...] Read more.
Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) in 13 of these genes to predict tumour response and clinical outcome measured as progression free survival (PFS) and overall survival (OS) in 57 patients with metastatic colorectal cancer (mCRC) given bevacizumab plus chemotherapy. SNPs were detected (iPLEX® Assay) in genomic DNA extracted from formalin-fixed paraffin-embedded tumour specimens. The variant allele CD39 rs11188513 was associated with a good tumour response (p = 0.024). Patients homozygous for the wild-type allele FGF2 rs1960669 showed a median PFS of 10.95 months versus 5.44 months for those with at least one variant allele-A (HR 3.30; 95% CI: 1.52–7.14; p = 0.001). Patients homozygous for wild-type MMP9 rs2236416 and rs2274755 showed a median PFS of 9.48 months versus 6 and 6.62 months, respectively, for those with at least one variant allele (p = 0.022, p = 0.043, respectively). OS was also lengthened to 30.92 months (p = 0.034) in carriers of wild-type ANGPT1 rs2445365 versus 22.07 months for those carrying at least one variant allele-A. These gene variants were able to predict clinical outcome and tumour response in mCRC patients given bevacizumab-based therapy. Full article
(This article belongs to the Special Issue Gender Medicine: Pharmacogenetics and Personalised Medicine 2.0)
Show Figures

Figure 1

Back to TopTop